Metformin: A Comprehensive Review of Mechanisms, Clinical Applications, and Future Directions

Abstract

Metformin, a biguanide derivative, remains the cornerstone of pharmacological management for type 2 diabetes mellitus (T2DM), particularly in overweight or obese individuals. Its enduring popularity stems from its efficacy in lowering blood glucose, its relatively benign side effect profile, and its association with a reduced risk of cardiovascular events in some studies. This comprehensive review delves into the history of metformin, elucidating its serendipitous discovery and subsequent development into a widely prescribed medication. We explore its complex mechanism of action, focusing on its effects on hepatic glucose production, insulin sensitivity, and gut microbiome modulation. The report also addresses common and less common side effects, contraindications, and considerations for use in various patient populations, including those with renal impairment and older adults. Furthermore, we examine the evolving evidence base supporting metformin’s potential benefits beyond glycemic control, such as its anti-cancer properties, neuroprotective effects, and impact on aging. Finally, we discuss ongoing research efforts aimed at optimizing metformin therapy and identifying novel therapeutic targets based on its multifaceted mechanisms of action.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Type 2 diabetes mellitus (T2DM) is a global health crisis, affecting hundreds of millions worldwide and imposing a significant burden on healthcare systems. Effective management of T2DM necessitates a multifaceted approach encompassing lifestyle modifications, pharmacological interventions, and, in some cases, bariatric surgery. Metformin, a biguanide, has consistently held its position as the first-line pharmacological agent for T2DM, recommended by leading diabetes organizations like the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [1]. Its effectiveness, safety, and affordability have cemented its role in T2DM management for decades.

However, the mechanisms underlying metformin’s therapeutic effects are complex and not fully understood. While its primary action is believed to be the reduction of hepatic glucose production, metformin also influences insulin sensitivity, glucose uptake in peripheral tissues, and the gut microbiome. Moreover, emerging evidence suggests potential benefits beyond glycemic control, including anti-cancer properties, cardiovascular protection, and even effects on aging. This review aims to provide a comprehensive overview of metformin, encompassing its history, mechanisms of action, clinical applications, potential benefits, and ongoing research directions, thereby offering an expert-level understanding of this widely used medication.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Historical Perspective

The origins of metformin can be traced back to Galega officinalis, also known as French lilac or goat’s rue, a plant used in traditional European medicine for its blood glucose-lowering properties. Guanidine, a compound isolated from Galega officinalis, was found to possess hypoglycemic activity but was deemed too toxic for human use. Research efforts then focused on synthesizing less toxic guanidine derivatives, leading to the development of biguanides in the 1920s. Phenformin and buformin were among the first biguanides introduced for the treatment of diabetes. However, due to a higher risk of lactic acidosis, particularly with phenformin, these agents were eventually withdrawn from the market in many countries [2].

Metformin, synthesized in 1922, was initially overlooked due to the focus on insulin therapy. Jean Sterne, a French physician, recognized its potential in treating diabetes in the late 1950s and introduced it under the trade name Glucophage (glucose eater). Metformin’s introduction was initially slower than that of other biguanides, but its safety profile, particularly the lower risk of lactic acidosis compared to phenformin, eventually led to its widespread adoption. It received approval for use in the United States in 1995 and has since become the most commonly prescribed oral antidiabetic drug worldwide [3].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Mechanism of Action

Metformin’s mechanism of action is multifaceted and involves several pathways. While the precise molecular mechanisms remain under investigation, the prevailing understanding centers on its effects on hepatic glucose production, insulin sensitivity, and gut microbiome modulation.

3.1. Hepatic Glucose Production

The primary mechanism by which metformin lowers blood glucose is through the reduction of hepatic glucose production (HGP). Metformin inhibits both gluconeogenesis (the synthesis of glucose from non-carbohydrate precursors) and glycogenolysis (the breakdown of glycogen into glucose) in the liver. This effect is mediated, at least in part, through the activation of adenosine monophosphate-activated protein kinase (AMPK), a cellular energy sensor [4]. AMPK activation in hepatocytes leads to the phosphorylation and inactivation of key enzymes involved in gluconeogenesis, such as fructose-1,6-bisphosphatase and phosphoenolpyruvate carboxykinase (PEPCK). It also suppresses the expression of genes encoding these enzymes.

However, recent evidence suggests that the AMPK-independent mechanisms may also contribute significantly to metformin’s effects on HGP. These mechanisms may involve the inhibition of mitochondrial respiratory chain complex I, which leads to a reduction in cellular energy charge and activation of AMPK. This inhibition also alters hepatic redox state and intracellular signaling pathways, ultimately reducing HGP [5]. The relative contribution of AMPK-dependent and AMPK-independent mechanisms to metformin’s overall effect on HGP remains an area of active investigation.

3.2. Insulin Sensitivity

In addition to reducing HGP, metformin also improves insulin sensitivity in peripheral tissues, primarily muscle and adipose tissue. This effect is thought to be mediated by increasing glucose uptake and utilization in these tissues. While the exact mechanisms are not fully elucidated, metformin may enhance insulin signaling by promoting the translocation of glucose transporter 4 (GLUT4) to the cell surface, thereby facilitating glucose entry into cells [6]. Metformin may also improve insulin sensitivity by modulating lipid metabolism and reducing intracellular lipid accumulation in muscle and liver.

3.3. Gut Microbiome Modulation

Emerging evidence highlights the role of the gut microbiome in mediating metformin’s effects. Metformin can alter the composition and function of the gut microbiome, leading to increased abundance of certain bacterial species and decreased abundance of others. These changes in the gut microbiome can influence glucose metabolism, insulin sensitivity, and inflammation [7]. Specifically, metformin has been shown to increase the abundance of Akkermansia muciniphila, a bacterium associated with improved glucose metabolism and reduced inflammation. The gut microbiome also plays a role in the production of short-chain fatty acids (SCFAs), which can modulate glucose homeostasis. Further research is needed to fully elucidate the complex interplay between metformin, the gut microbiome, and metabolic health.

3.4. Other Mechanisms

Beyond its effects on HGP, insulin sensitivity, and the gut microbiome, metformin may exert its effects through other mechanisms, including:

• Reduced intestinal glucose absorption: Metformin can decrease glucose absorption from the small intestine, contributing to lower postprandial glucose levels [8].
• Increased incretin secretion: Metformin may stimulate the secretion of glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances insulin secretion and suppresses glucagon secretion [9].
• Modulation of bile acid metabolism: Metformin can influence bile acid metabolism, which may have implications for glucose and lipid homeostasis [10].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Clinical Applications and Efficacy

Metformin is primarily indicated for the treatment of T2DM, particularly in overweight or obese individuals. It is often used as a first-line agent, either alone or in combination with other antidiabetic medications, including sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and insulin. Clinical trials have consistently demonstrated metformin’s efficacy in lowering blood glucose levels, as measured by HbA1c, fasting plasma glucose, and postprandial glucose [11].

4.1. Monotherapy

As monotherapy, metformin has been shown to effectively reduce HbA1c levels by 1-2%, depending on the patient’s baseline HbA1c and adherence to therapy [12]. Its effectiveness is comparable to that of other oral antidiabetic agents, such as sulfonylureas. However, metformin is often preferred over sulfonylureas due to its lower risk of hypoglycemia and weight gain.

4.2. Combination Therapy

Metformin is frequently used in combination with other antidiabetic medications to achieve optimal glycemic control. It complements the mechanisms of action of other agents, such as sulfonylureas (which stimulate insulin secretion), thiazolidinediones (which improve insulin sensitivity), DPP-4 inhibitors (which enhance incretin action), SGLT2 inhibitors (which increase urinary glucose excretion), and insulin (which replaces or supplements endogenous insulin production) [13]. Combination therapy with metformin is often necessary to achieve target HbA1c levels, particularly as T2DM progresses.

4.3. Specific Patient Populations

• Overweight and Obese Individuals: Metformin is particularly effective in overweight and obese individuals with T2DM, as it can help improve insulin sensitivity and reduce weight gain. Some studies have even shown a modest weight loss with metformin treatment [14].
• Patients with Polycystic Ovary Syndrome (PCOS): Metformin is used off-label to treat PCOS, a common endocrine disorder that affects women of reproductive age. Metformin can improve insulin sensitivity, reduce androgen levels, and promote ovulation in women with PCOS [15].
• Patients with Prediabetes: Metformin has been shown to prevent or delay the progression of prediabetes to T2DM in some individuals. The Diabetes Prevention Program (DPP) demonstrated that metformin was effective in reducing the risk of developing T2DM in individuals with prediabetes [16].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Side Effects and Contraindications

Metformin is generally well-tolerated, but it can cause side effects in some individuals. The most common side effects are gastrointestinal (GI) disturbances, such as nausea, vomiting, diarrhea, and abdominal discomfort. These side effects are usually mild and transient and can be minimized by starting with a low dose and gradually increasing it over several weeks. Taking metformin with meals can also help reduce GI side effects.

5.1. Common Side Effects

• Gastrointestinal Disturbances: As mentioned above, GI side effects are the most common. Extended-release formulations of metformin may be better tolerated than immediate-release formulations [17].
• Metallic Taste: Some individuals report a metallic taste in their mouth while taking metformin.
• Vitamin B12 Deficiency: Long-term metformin use can lead to vitamin B12 deficiency in some individuals, particularly those with underlying risk factors, such as older age, poor diet, or malabsorption disorders. Regular monitoring of vitamin B12 levels and supplementation may be necessary [18].

5.2. Less Common but Serious Side Effects

• Lactic Acidosis: Lactic acidosis is a rare but serious complication of metformin use. It is characterized by a buildup of lactic acid in the blood, which can lead to symptoms such as nausea, vomiting, abdominal pain, muscle weakness, and respiratory distress. Lactic acidosis is more likely to occur in individuals with underlying renal impairment, liver disease, or heart failure. The risk of lactic acidosis with metformin is significantly lower than with phenformin, but it remains a concern [19].

5.3. Contraindications

Metformin is contraindicated in individuals with:

• Severe Renal Impairment: Metformin is primarily eliminated by the kidneys, and its use is contraindicated in individuals with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2. Use in those with an eGFR between 30-45 mL/min/1.73 m2 is generally not recommended, and dosage adjustments may be necessary.
• Severe Liver Disease: Metformin is contraindicated in individuals with severe liver disease, as it can impair hepatic glucose production and increase the risk of lactic acidosis.
• Acute or Unstable Heart Failure: Metformin is generally not recommended in individuals with acute or unstable heart failure due to the increased risk of lactic acidosis.
• Alcohol Abuse: Excessive alcohol consumption can increase the risk of lactic acidosis in individuals taking metformin.
• Conditions Predisposing to Tissue Hypoxia: Any condition that can lead to tissue hypoxia, such as severe infection or sepsis, can increase the risk of lactic acidosis in individuals taking metformin.

5.4. Considerations for Special Populations

• Older Adults: Metformin can be used in older adults with T2DM, but caution is advised due to the increased risk of renal impairment. Renal function should be carefully monitored, and dosage adjustments may be necessary [20].
• Pregnancy and Breastfeeding: Metformin is generally not recommended during pregnancy or breastfeeding. Insulin is typically the preferred treatment option for gestational diabetes and T2DM in pregnant women. While some studies have suggested potential benefits of metformin in pregnancy (e.g., in women with PCOS), more research is needed to confirm its safety and efficacy [21].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Potential Benefits Beyond Diabetes Treatment

Emerging evidence suggests that metformin may have potential benefits beyond glycemic control, including anti-cancer properties, neuroprotective effects, and effects on aging. These potential benefits have generated considerable interest in the scientific community and are the subject of ongoing research.

6.1. Anti-Cancer Properties

Several epidemiological studies have suggested that metformin use is associated with a reduced risk of certain types of cancer, including colorectal cancer, breast cancer, prostate cancer, and endometrial cancer [22]. In vitro and in vivo studies have shown that metformin can inhibit cancer cell growth, proliferation, and metastasis through various mechanisms, including AMPK activation, inhibition of mTOR signaling, and modulation of the tumor microenvironment. Clinical trials are ongoing to evaluate the efficacy of metformin as an adjunct therapy for cancer treatment.

6.2. Neuroprotective Effects

Metformin has also been shown to have neuroprotective effects in preclinical studies. It can protect against neuronal damage caused by oxidative stress, inflammation, and excitotoxicity. Some studies have suggested that metformin may reduce the risk of Alzheimer’s disease and other neurodegenerative disorders, but more research is needed to confirm these findings [23]. Metformin may exert its neuroprotective effects by improving insulin sensitivity in the brain, reducing inflammation, and promoting neuronal survival.

6.3. Effects on Aging

Metformin has garnered attention as a potential anti-aging agent. Studies in model organisms, such as C. elegans and mice, have shown that metformin can extend lifespan and improve healthspan. Metformin may exert its anti-aging effects by activating AMPK, improving mitochondrial function, and reducing oxidative stress. The TAME (Targeting Aging with Metformin) trial is a clinical trial designed to evaluate the effects of metformin on aging-related outcomes in humans [24].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Ongoing Research and Future Directions

Research on metformin continues to expand, focusing on elucidating its complex mechanisms of action, optimizing its clinical use, and exploring its potential benefits beyond diabetes treatment. Key areas of ongoing research include:

• Mechanism of Action: Further investigation into the relative contributions of AMPK-dependent and AMPK-independent mechanisms to metformin’s effects on HGP, insulin sensitivity, and gut microbiome modulation.
• Novel Therapeutic Targets: Identification of novel therapeutic targets based on metformin’s multifaceted mechanisms of action, such as specific AMPK isoforms or gut microbiome components.
• Personalized Medicine: Development of strategies for personalizing metformin therapy based on individual patient characteristics, such as genetic factors, gut microbiome composition, and response to treatment.
• Combination Therapies: Evaluation of novel combination therapies involving metformin and other antidiabetic agents or lifestyle interventions to achieve optimal glycemic control and reduce cardiovascular risk.
• Clinical Trials: Large-scale clinical trials to evaluate the efficacy of metformin as an adjunct therapy for cancer treatment, neurodegenerative disorders, and aging-related conditions.
• New Formulations: Development of new formulations of metformin, such as sustained-release or targeted delivery systems, to improve tolerability and bioavailability.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Conclusion

Metformin remains a cornerstone of T2DM management, owing to its efficacy, safety, and affordability. Its primary mechanism of action involves the reduction of hepatic glucose production, but it also influences insulin sensitivity and gut microbiome modulation. While generally well-tolerated, metformin can cause GI side effects and, rarely, lactic acidosis. Emerging evidence suggests potential benefits beyond glycemic control, including anti-cancer properties, neuroprotective effects, and effects on aging. Ongoing research efforts are aimed at optimizing metformin therapy and identifying novel therapeutic targets based on its multifaceted mechanisms of action. As our understanding of metformin’s complex effects continues to evolve, its role in managing T2DM and potentially other age-related diseases will likely expand.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement_1), S1-S291.

[2] Bailey, C. J., & Nattrass, M. (2004). Metformin. The New England Journal of Medicine, 351(11), 1150-1151.

[3] Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. Diabetologia, 60(9), 1577-1585.

[4] Viollet, B., Guigas, B., Leclerc, J., Beauloye, V., & Andréelli, F. (2003). AMP-activated protein kinase in the regulation of hepatic glucose production. Best Practice & Research Clinical Endocrinology & Metabolism, 17(4), 537-550.

[5] Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014). Metformin: from mechanisms to the bedside. Diabetologia, 57(11), 2355-2369.

[6] Hundal, R. S., Ramlal, T., Reyes, R., Ahmed, N., Gray, G. A., & Klip, A. (1992). Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology, 131(3), 1163-1174.

[7] Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Prifti, E., … & Bork, P. (2015). Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature, 528(7581), 262-266.

[8] Bailey, C. J., Wilcock, C., & Day, C. (2008). Effect of metformin on glucose metabolism in the in situ perfused rat small intestine. British Journal of Pharmacology, 153(6), 1145-1152.

[9] Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Rotella, C. M., & Alberti, L. (2001). Effect of metformin on glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) secretion in obese diabetic patients. Diabetes, Obesity and Metabolism, 3(5), 315-318.

[10] Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002). Metformin and the kidney: Friend or foe?. Diabetes/Metabolism Research and Reviews, 18(2), 85-96.

[11] DeFronzo, R. A., Goodman, A. M., & Multicenter Metformin Study Group. (1995). Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The New England Journal of Medicine, 333(9), 541-549.

[12] Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32(1), 193-203.

[13] Bennett, W. L., Maruthur, N. M., Crager, S., Edwards, A. L., Appiah, M., Wilson, L. M., … & Segal, J. B. (2011). Comparative effectiveness and safety of medications for type 2 diabetes: an update. Annals of Internal Medicine, 154(9), 602-613.

[14] Seifarth, C., Schehler, B., & Schneider, H. J. (2013). Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Experimental and Clinical Endocrinology & Diabetes, 121(1), 27-31.

[15] Palomba, S., Pasquali, R., & Genazzani, A. D. (2009). Metformin and polycystic ovary syndrome: systematic review of randomized clinical trials. The Journal of Clinical Endocrinology & Metabolism, 94(8), 2761-2772.

[16] Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346(6), 393-403.

[17] Blonde, L., Dailey, G. E., Jabbour, S. A., Reasner, C. A., & Mills, D. J. (2004). Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a double-blind, placebo-controlled trial. Current Medical Research and Opinion, 20(4), 565-572.

[18] de Jager, J., Kooy, A., Lehert, P., Wulffelé, M. G., van der Kolk, J., Bets, D., … & Stehouwer, C. D. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ, 340, c2181.

[19] Lalau, J. D. (2010). Lactic acidosis induced by metformin: incidence, risk factors and mechanisms. Drug Safety, 33(9), 727-740.

[20] Bell, S., Bailey, C. J., & Holman, R. R. (2016). Metformin in type 2 diabetes mellitus and risk of lactic acidosis. Diabetes Care, 39(3), e40-e41.

[21] Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., Moore, M. P., & O’donoghue, K. (2008). Metformin versus insulin for the treatment of gestational diabetes. The New England Journal of Medicine, 358(19), 2003-2015.

[22] Dowling, R. J., Goodwin, P. J., & Stambolic, V. (2011). Metformin for cancer prevention and treatment. Annals of the New York Academy of Sciences, 1228(1), 196-210.

[23] Campbell, J. M., Walker, M., Lindsay, R. S., Noonan, J., Bell, D. S., & Baker, W. L. (2017). Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes: a systematic review and meta-analysis. Ageing Research Reviews, 40, 40-48.

[24] Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016). Metformin as a tool to target aging. Cell Metabolism, 23(6), 1060-1065.